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A B S T R A C T
Statins significantly reduce cardiovascular events by reducing low-density-lipopro-
tein cholesterol (LDL-C). However, despite achieving the LDL goals, a substantial 
residual risk remains. It appears that low levels of high-density lipoprotein choles-
terol (HDL-C) constitute another independent risk factor for coronary artery disease 
(CAD). Therefore, raising HDL levels appears an attractive target to further reduce 
the cardiovascular risk. However, classical HDL-reducing drugs (nicotinic acid de-
rivatives, fibrates) are not well tolerated and newer agents (torcetrapid), which seemed 
effective in doing that, had to be withdrawn due to increased mortality. Nevertheless, 
due to the importance of HDL in influencing the cardiovascular risk, efforts in devel-
oping safer drugs are continuing. Such pharmacological developments, as well as the 
nonpharmacological approaches to increase HDL, and other HDL-targeted therapies 
are discussed in this overview.
I N T R O D U C T I O N
Cardiovascular disease remains the leading cause of morbidity and mortality in 
the developed countries. Over the last two decades we have witnessed an impressive 
reduction in cardiovascular risk mainly with the use of 3-hydroxy-3-methylglutaryl 
coenzyme A inhibitors (statins), which are directed to reduce low-density-lipoprotein 
cholesterol (LDL-C). The use of these drugs has resulted in a 21% reduction in the 
risk of major cardiovascular (CV) events, for every 39 mg/dl (1 mmol/l) decrease 
in LDL-C.1 More aggressive LDL lowering using high-dose statins has led to even 
greater reductions in the risk of future CV events.2,3 However, despite achieving the 
LDL goals recommended by ATP III guidelines,4 a substantial residual risk remains, 
and it appears that an approximate 70% of coronary events have not been prevented 
in statin trials.5,6 On the other hand, early epidemiological data showed that low levels 
of high-density lipoprotein cholesterol (HDL-C) constitute an independent risk factor 
for coronary artery disease (CAD).7 Therefore, raising HDL levels appears an attrac-
tive target in the effort of further reducing cardiovascular risk.
E P I D E M I O L O G Y
From the 1970s, the Framingham study showed that low HDL levels were associated 
with increased risk of cardiovascular events. More recent data confirm these observa-
tions, suggesting that a 2-3% increase in CV risk results from every 1mg/dl decrease in 
HDL-C.8 The inverse relationship between HDL and CAD was also demonstrated in 
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ABBREVIATIONS
CAD = coronary artery disease
CETP = cholesteryl ester transfer protein
CV = cardiovascular
HDL = high-density lipoprotein
IVUS = intravascular ultrasound
LDL = low density lipoprotein
NO = nitric oxide
VLDL = very low density lipoprotein
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the PROCAM study, where patients with HDL-C <35 mg/dl 
had a 70% increased risk of developing CAD, compared to 
those with an HDL-C above this value.9
The prevalence of dyslipidemia varies with the population 
being studied and abnormalities in lipoprotein metabolism 
are more common in subjects with premature CAD than age-
matched controls. There are several studies, suggesting that 
low levels of HDL are quite common in the general popula-
tion, affecting 33% of men and 40% of women.10 It should 
also be noted that low HDL is frequently a component of the 
metabolic syndrome, which affects 24% of adults older than 
20 years in the US.11,12 In these patients, as well as in those 
with type 2 diabetes mellitus, low HDL levels coexist with high 
triglycerides and small, dense LDL particles which consist the 
“lipid triad”. It is therefore not surprising that the third report 
of the National Cholesterol Education Program (NCEP) ATP 
III guidelines, consider HDL levels below 40 mg/dl as an inde-
pendent major risk factor for CAD, which should be addressed 
after the LDL and triglyceride goals are met.4
H D L  M E T A B O L I S M  A N D  P L E I O T R O P I C 
E F F E C T S
Although traditionally thought to protect against car-
diovascular disease through reverse cholesterol transport, 
HDL acts through multiple pathways that are sometimes 
incompletely understood. In other words, HDL also exerts 
antiatherogenic effects that are non-cholesterol dependent.13 
Antioxidant, antiapoptotic, anti-inflammatory, antithrom-
botic and direct endothelial effects of HDL have all been 
investigated and possibly contribute to its antiatherogenic 
properties.
R E V E R S E  C H O L E S T E R O L  T R A N S P O R T
The metabolism of lipid molecules in the human body 
involves the transfer of cholesterol from the liver to the pe-
riphery, to be used for cell membrane integrity and steroid 
hormone synthesis, which is mediated by Apo- B containing 
lipoproteins (VLDL and LDL) and the transfer of cholesterol 
in the opposite direction i.e. from periphery to the liver, which 
is mediated by Apo A-I containing lipoproteins (HDL). The 
latter process is known as “reverse cholesterol transport”.14
The major apolipoprotein of HDL is Apo A-I, comprising 
70% of HDL protein. The liver and intestine synthesize Apo 
A-I which interacts with adenosine-triphosphate-binding cas-
sette transporter A1 (ABCA1), located in the macrophages 
in order to achieve the transfer of free cholesterol from foam 
cells to the lipid-poor Apo A-I. Thus, nascent pre-b-HDL 
is created, which is converted to mature a-HDL (HDL2 
and HDL3). HDL2 particles are smaller and denser, while 
HDL3 particles are larger and less dense. The interconversion 
between the two is achieved via the action of the enzymes, 
hepatic and endothelial lipase and lecithin-cholesterol acyl-
transferase (LCAT). Those mature HDL particles can accept 
more cholesterol from the macrophages via the ATP-binding 
cassette transporter G1 (ABCG1). The cholesterol obtained 
from the periphery can then be returned to the liver via two 
pathways. In the direct pathway, cholesteryl esters are taken by 
hepatocytes via the scavenger receptor type B1 (SRB1). In the 
indirect pathway, there is an exchange of cholesteryl esters for 
triglycerides between the mature HDL particles and VLDL 
and LDL, which is mediated by the enzyme cholesteryl ester 
transfer protein (CETP). HDL is enriched in triglycerides, 
while VLDL and LDL transfer their cholesteryl esters back to 
the liver via the LDL receptor. The latter mechanism may be 
responsible for 50% of cholesterol transfer back to the liver. 
The process of reverse cholesterol transport provides the most 
common explanation for the antiatherogenic effects of HDL, 
as cholesterol is taken from the periphery i.e. macrophages and 
foam cells and returned back to the liver to be excreted into 
the bile and gut. However, as already mentioned, HDL has 
other antiatherogenic properties that contribute to improve 
endothelial function and reduce the overall CV risk.
E N D O T H E L I A L  A C T I O N S  O F  H D L
There are studies which suggest that HDL increases nitric 
oxide (NO) production from nitric oxide synthase (eNOS).15,16 
NO bioavailability is known to be impaired in the early stages 
of atheroma formation. In addition, therapies directed to in-
crease HDL, like nicotinic acid17 and infusion of Apo A-I,18, 19 
have been shown to improve endothelial function. There are 
also data which show that HDL-C improves the proliferation 
and migration of endothelial cells, thus promoting the integrity 
of the inner layer of blood vessels.
A N T I O X I D A N T  E F F E C T S  O F  H D L
The oxidation of LDL is an important step in the formation 
of fatty streaks at the initial stages of atheroma development. 
HDL particles carry enzymes such as paraoxonase 1 and 
LCAT which, along with Apo A-I, exert antioxidant effects by 
inhibiting phospholipid oxidation that leads to the production 
of minimally modified LDL.20,21 Interestingly, a recent study 
showed that low paraoxonase 1 activity was an independent 
predictor of coronary events.22
A N T I A P O P T O T I C  E F F E C T S  O F  H D L
Several particles such as oxidized LDL, TNFa and homo-
cysteine contribute to the apoptotic cell death of endothelial 
cells, thus promoting disruption of the inner layer of blood ves-
sels and inducing acute thrombotic events. There is evidence 
that HDL decreases endothelial cell apoptosis through several 
mechanisms, involving the TNFa pathway and the activation 
of protein kinase Akt.23,24
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A N T I T H R O M B O T I C  E F F E C T S  O F  H D L
There is growing evidence that HDL particles have anti-
thrombotic properties. The above mentioned increase in NO 
levels, along with increased prostacyclin release, as well as the 
decrease in the activity of adhesion molecules and the anti-
apoptotic activity, act in concert to prevent thrombus forma-
tion.25-27 In addition the sphingolipids, contained in the HDL 
particles, exert various antithrombotic effects. Finally, HDL 
also acts as an anticoagulant factor enhancing the inactivation 
of Factor Va by activated protein C and protein S.28
A N T I I N F L A M M A T O R Y  E F F E C T S  O F  H D L
Atheroma formation is definitely an inflammatory process. 
The expression of adhesion molecules such as vascular cell 
adhesion molecule (VCAM-1) and intercellular adhesion 
molecule (ICAM-1), leads to the attachment of monocytes 
to endothelial cells. The migration of the former to the sub-
endothelial layer is stimulated by chemoattractants such as 
monocytes chemotactic protein-1 (MCP-1). HDL particles 
interrupt the TNFa stimulation of the adhesion molecules and 
also neutralize CRP’s proinflammatory activity.29,30
N O N - P H A R M A C O L O G I C A L  A P P R O A C H 
T O  I N C R E A S E  H D L  L E V E L S
A E R O B I C  E X E R C I S E
Aerobic exercise has been reported to increase HDL levels 
by 5-10%. Ideally, one should exercise briskly for 30 minutes, 
5 times per week, and the strongest determinant of achieving 
optimal HDL levels is the total duration of exercise exceeding 
120 minutes per week.4,31 The patients most likely to benefit 
from exercise are males with low HDL levels, high triglycerides 
and abdominal obesity.32
S M O K I N G  C E S S A T I O N
Smoking is known to reduce HDL levels although the 
mechanism remains elusive. Nevertheless, tobacco cessation 
is said to increase HDL levels by 5-10% and should be strongly 
encouraged via a multidisciplinary approach involving coun-
seling and if necessary appropriate medications. Smoking 
also constitutes a source of oxidative stress that can impair 
the function of HDL.4,33 One study showed that smoking ces-
sation led to an increase in HDL by 4 mg/dl.34
W E I G H T  R E D U C T I O N
It is well known that obesity and in particular visceral 
obesity is associated with high levels of triglycerides, low levels 
of HDL and small, dense LDL particles. The patients who 
derive most benefit from weight loss in terms of HDL raising, 
are the overweight or obese ones. It has been reported that 
for every kilogram lost, an increase of 0.35 mg/dl is observed 
in HDL-C.35 It is worth mentioning that according to ATP 
III guidelines, overweight and obese individuals should aim 
for a body mass index of less than 25, and the rate of weight 
reduction should be 2 kg per month.4 In addition, weight loss 
also improves other cardiometabolic risk factors.
D I E T A R Y  M O D I F I C A T I O N S
Although the consumption of saturated and trans-fatty 
acids, increases HDL levels, it also increases LDL levels as 
well as the expression of adhesion molecules.36 It appears that 
the consumption of n-3 polyunsaturated fatty acids increases 
HDL levels and provide cardiovascular benefits.37 Moreover, 
a recent study showed that a low-fat, and rich in fibers diet, 
along with exercise is helpful in improving the quality of HDL 
particles, increasing their anti-inflammatory properties.38 
Therefore, patients should be advised to replace saturated and 
trans fatty acids with monounsaturated and n-3 polyunsatu-
rated ones, consuming plant oils, nuts and fish.4
A L C O H O L  C O N S U M P T I O N
The beneficial effects of mild to moderate alcohol con-
sumption on CV risk have been known for many years. It ap-
pears that 1-3 drinks per day offer some degree of protection, 
via various mechanisms, but they also increase HDL levels.39,40 
Of course every benefit will be lost if the alcohol consumption 
is not kept within the limits stated by the ATP III guidelines.4 
Moreover it appears that the benefits of alcohol are influenced 
by the patients’ age and gender.
P H A R M A C O L O G I C A L  A P P R O A C H E S  
T O  I N C R E A S E  H D L
N I C O T I N I C  A C I D  ( N I A C I N )
Nicotinic acid is part of the Vitamin B complex and has 
been in use for the treatment of hyperlipidemia for the past 50 
years. When tolerated, it is the most effective HDL-C increas-
ing agent currently available. It has been shown to increase 
HDL-C by 15-35%, and a recent meataanalysis showed an 
average increase of 16%.41 There are several mechanisms 
through which niacin increases HDL levels. It reduces VLDL 
synthesis by the liver and therefore attenuates the exchange of 
triglycerides for cholesterol mediated by CETP. This results 
in larger HDL particles, containing more cholesterol, which 
have delayed catabolism.42 Secondly, nicotinic acid reduces 
the uptake of HDL by the liver.43 Thirdly, it enhances reverse 
cholesterol transport via ABCA-1.44 Finally, a recent study 
showed that niacin stimulates Apo A-I synthesis.45 Other 
favorable effects of nicotinic acid on lipid metabolism include 
lowering of LDL and triglycerides as well as lipoprotein Lp(a) 
levels.46 It appears that LDL particles are converted from 
small, dense and therefore more atherogenic to larger, buoyant 
and less harmful ones.
Many studies have proven the efficacy of nicotinic acid in 
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augmenting HDL-C with favorable clinical outcomes. The 
Coronary Drug Project, where niacin was used in patients 
with a history of myocardial infarction, demonstrated a 
reduction in CAD death, non-fatal myocardial infarction, 
cerebrovascular events and, although not shown at first, an 
11% mortality reduction which became apparent 9 years after 
the termination of the trial.47 Several studies have tested the 
efficacy of nicotinic acid combined with fibrates and bile acid 
sequestrants, all showing favorable outcomes on cardiovascu-
lar events.48-50
Niacin has also been combined with simvastatin in a study 
that tested their efficacy as well as the use of antioxidants in 
patients with clinical and angiographic evidence of CAD, nor-
mal LDL-C and low HDL-C.51 The combination arm resulted 
in substantial decrease in LDL levels and a 26% increase in 
HDL-C. Angiographic regression was also observed in the 
simvastatin plus niacin arm and these patients were signifi-
cantly less likely to have a first cardiovascular event (death, 
myocardial infarction, stroke, or revascularization). The study 
also showed that the use of antioxidants was not beneficial, 
which is also the conclusion of most other clinical trials. The 
efficacy of extended-release niacin on CAD patients with low 
HDL-C, already receiving a statin was tested in ARBITER-
2 study, where the levels of HDL-C increased by 8 mg/dl on 
average and there was a trend towards decreased progression 
of carotid intima-media thickness at one year.52
Unfortunately the side effects of nicotinic acid, mainly 
facial flushing, pruritus and hepatotoxicity, have limited its 
use. Flushing is initially seen in 80% of patients and disap-
pears over time. It is caused by stimulated biosynthesis of 
prostaglandin D2 which acts as a vasodilator. Laropiprant, 
a selective antagonist of the prostaglandin D2 receptor, was 
shown to reduce flushing, resulting in less patients discontinu-
ing the medication.53 Flushing is also reduced by the use of 
a longer-acting formulation of nicotinic acid instead of the 
immediate release one. The former has been shown to be 
equally effective in increasing HDL-C.54 Interestingly, recent 
data show that flushing may be a sign of a good response to 
HDL levels, as patients in the ARBITER-2 study who reported 
flushing had a greater increase in HDL-C, compared to those 
without flushing.55 The effects of combining simvastatin with 
prolonged-acting niconitic acid will be addressed in the AIM-
HIGH study which enrolls patients with known cardiovascular 
disease with raised triglycerides and low HDL-C. Although 
there has been some concern about niacin disturbing glycemic 
control in diabetics with dyslipidemia, recent data have not 
shown any significant effect on glucose levels.56,57
S T A T I N S
Statins are known to modestly increase HDL-C by 5-15% 
and this is more pronounced with rosuvastatin.58 Statins in-
crease hepatic Apo A-I synthesis, decrease levels of CETP and 
increase the activity of the antioxidant enzyme paraoxonase. 
Statins are known to have other beneficial effects besides 
LDL lowering. Nevertheless, patients in the heart Protection 
Study who had lower HDL-C levels, had a greater reduction 
in CV risk.59 However, despite the great benefits derived 
from statin therapy, the only modest increase in HDL-C 
does not permit their use as monotherapy when the target is 
to increase HDL.
F I B R I C  A C I D  D E R I VA T I V E S  ( F I B R A T E S )
Fibrates act on peroxisome proliferator-activated receptor 
a (PPARa), a nuclear receptor which activates genes for Apo 
A-I and Apo A-II. With the increase in lipoprotein lipase 
activity, fibrates clear VLDL particles and lower triglycerides. 
As a result, they increase HDL-C by 10-20%, lower LDL-C 
by 10-15% and mostly reduce triglycerides by 40-50%. Both 
the Helsinki Heart Study 60 and the VA-HIT study,61 treat-
ment with gemfibrozil reduced cardiovascular events. In fact 
the VA-HIT trial was the first to demonstrate the beneficial 
effect of HDL-C raising on major coronary events, as a mul-
tivariate analysis correlated the CAD death and nonfatal MI 
with the levels of HDL-C independently of LDL and triglyc-
erides.62 One should bear in mind that the combination of 
statins with fibrates, and in particular gemfibrozil, should be 
closely monitored due to the increased risk of myopathy and 
rhabdomyolysis. The role of fibrates is mainly in the treatment 
of hypertriglyceridaemia and potentially in the treatment of 
high-risk patients with low HDL and high triglycerides.
N O V E L  H D L - T A R G E T E D  T H E R A P I E S
C E T P  I N H I B I T O R S
The enzyme cholesterol ester transfer protein (CETP) 
holds a key role in reverse cholesterol transport, as already 
mentioned, since it exchanges cholesterol esters for triglyc-
erides, permitting the uptake of cholesterol esters by the 
hepatocytes via the LDL receptor. Inhibition of CETP activity 
has resulted in increased levels of HDL and reduced levels 
of VLDL, LDL and triglycerides.63 Torcetrapib, was a direct 
CETP inhibitor which was shown to significantly increase 
HDL.64,65 Unfortunately, it was withdrawn from further de-
velopment as the results of the ILLUMINATE trial,66 where 
patients were treated with atorvastatin and torcetrapib or 
atorvastatin alone, showed a significant increase of cardiovas-
cular events as well as all-cause mortality in the torcetrapib 
arm. This was despite a significant increase in HDL-C levels 
(72%) and an additional reduction in LDL-C. The disappoint-
ing results led to the early discontinuation of the trial. Three 
other trials with torcetrapib (ILLUSTRATE, RADIANCE 1 
and 2), showed no decrease in coronary atheroma as evaluated 
by IVUS and no change in carotid intima-media thickness, 
despite the increase in HDL-C.67-69
In the ILLUMINATE trial, a significant increase in blood 
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pressure of 5.4 mmHg, was observed, compared to the placebo 
group. This effect was also noted in the other torcetrapib trials 
and it appears to be a molecule-specific effect rather than a 
result of CETP inhibition. This could be one of the reasons 
that led to the negative results of ILLUMINATE. Other po-
tential explanations include the production of HDL particles 
that are defective in terms of reverse cholesterol transport, the 
production of pro-inflammatory HDL possibly through oxida-
tion of phospholipids and finally possible interactions between 
atorvastatin and torcetrapib.70 The above raise once more the 
issue of paying attention not only to the absolute HDL levels, 
but also to the quality of the HDL particles. For example, it 
is known that HDL2 particles, containing only Apo A-I, are 
mostly effective in the reverse cholesterol transport, while the 
HDL3 ones, containing both Apo A-I and Apo A-II, are less 
effective and indeed may increase visceral fat accumulation 
and impair VLDL metabolism.71,72
Newer CETP inhibitors include dalcetrapib and anace-
trapib. Dalcetrapib has been investigated in animal and human 
studies and it seems to significantly raise HDL-C without 
significant side-effects,73,74 both alone and in combination with 
statin therapy. Since the mechanism of action of dalcetrapib 
is different from that of torcetrapib, resulting in modulation 
rather than inhibition of CETP, the drug may prove valuable 
in the quest of raising HDL-C. Anacetrapib is another CETP 
inhibitor that has been tested in phase I and II clinical trials 
with encouraging results. The combination with atorvastatin 
resulted in significant LDL reduction and HDL increase, 
without any significant increase in blood pressure.75 Obviously, 
further research is needed before any definite recommenda-
tions can be made regarding the use of CETP inhibitors in 
clinical practice.
T H I A Z O L I D I N E D I O N E S  ( P PA R - γ  A G O N I S T S )
They are part of the PPAR agonist family which includes 
fibrates (PPARa agonists). Their use is in type II diabetes 
mellitus and they have been shown to increase HDL levels by 
5-15%.76,77 However, in a recent meataanalysis, rosiglitazone 
has been associated with a 40% increase in the risk of myo-
cardial infarction,78 possibly due to an LDL-increasing effect 
and the precipitation of heart failure in predisposed patients. 
A dual PPARa and PPAR γ agonist (muraglitazar) has been 
developed but despite increasing HDL-C by 16%, it has been 
withdrawn as it increased mortality, nonfatal myocardial 
infarction, stroke, transient ischemic attacks and congestive 
heart failure.79
C A N N A B I N O I D - 1  R E C E P T O R  B L O C K E R S
Rimonabant was the first cannabinoid receptor blocker 
that was used for managing obesity. In the hope to improve 
cardiometabolic risk, it was tested in overweight and obese 
patients, as well as in patients with type II diabetes mellitus 
and in the dose of 20 mg/day, it resulted in significant weight 
loss, reduction in waist circumference, and improvements 
in several metabolic risk factors. Rimonabant was found to 
increase HDL-C more than expected from weight loss alone, 
implicating a direct action on HDL metabolism.80,81 Unfortu-
nately, it was also shown to have significant central nervous 
system toxicity, mainly anxiety and depression, which led to 
its withdrawal from further clinical trials.
A P O  A - I  A N D  P H O S P H O L I P I D  T H E R A P I E S
Apo A-I Milano is a naturally occurring mutant of Apo 
A-I discovered in a small village in Italy, Limone sul Garda. 
Although it is associated with very low HDL levels, it does 
not result in clinical atherosclerosis.82 A recombinant form 
of Apo A-I Milano has been manufactured and tested in 
patients with acute coronary syndromes.83 Patients received 
5 weekly infusions of placebo or recombinant Apo A-I Mi-
lano at 15 mg/kg or 45 mg/kg and intravascular ultrasound 
was performed within 2 weeks following the acute coronary 
syndrome and repeated after 5 weekly treatments. The trial 
demonstrated a significant regression of coronary atheroscle-
rosis as measured by IVUS.
Reconstituted human HDL (rHDL) was tested in the 
ERASE trial,84 where patients were assigned to four weekly 
infusions of either placebo or two different doses of CSL-III, 
a reconstituted HDL consisting of Apo A-I from human 
plasma and soybean phosphatidylcholine. The results showed 
no significant reductions in percentage change in atheroma 
volume or nominal change in plaque volume, but there was a 
statistically significant improvement in the plaque character-
ization index on intravascular ultrasound, and coronary score 
on quantitative coronary angiography. The authors concluded 
that further research is warranted.
Apo A-I mimetics are peptides, smaller than the 243-
aminoacid Apo A-I, which are developed to resemble the 
lipid-binding domain of Apo A-I. An orally active compound, 
D-4F was shown to reduce atherosclerosis in mice.85 D-4F was 
recently tested in humans,86 showing that it has a low bioavail-
ability, which is improved under fasting conditions, and it was 
safe and well tolerated. It appears that the main mechanism 
of action of Apo A-I mimetic peptides is the remarkable 
binding affinity that oxidized lipids have for them, compared 
with Apo A-I.87 D-4F has also been reported to induce pre-β 
HDL formation which is the form of HDL the most active in 
promoting cholesterol efflux from macrophages via ABCA1 
transporter.88 Although preliminary, the above results indicate 
that Apo A-I mimetic peptides are a promising therapeutic 
strategy.87
Besides Apo A-I, the HDL particle consists, to a great 
extent of phospholipids and these have recently been tested as 
therapeutic options. An oral synthetic phospholipid (DMPC) 
was tested in a murine apoE null model, showing an increase 
in HDL levels and function, thereby reducing atherosclerosis.89 
Phosphatidylinositol, another phospholipid, was tested in hu-
HDL CHOLESTEROL
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mans and also demonstrated an increase in HDL-C and Apo 
A-I.90 A potential therapeutic target for the future is the inhibi-
tion of endolipase, which is an enzyme secreted by endothelial 
cells and hydrolyses HDL phospholipids, thereby reducing 
HDL levels. There is evidence that the levels of endolipase 
are inversely related to HDL levels.91 Lastly, the two main 
transporters for cholesterol efflux from macrophages to HDL 
are ABCA1 and ABCG1. Both of them are regulated by the 
nuclear liver X receptor (LXR). Therefore the stimulation of 
LXR would appear promising as a means to augment reverse 
cholesterol transport. The available data are yet limiting but 
show a positive effect on atherosclerosis progression.92,93
C O N C L U S I O N S
Over the last few decades we have witnessed a dramatic 
decrease in cardiovascular risk mainly by targeting LDL cho-
lesterol. The substantial residual risk that remains after statin 
treatment, represents a challenge and there are enough epide-
miological as well as experimental and clinical data to show 
that it can be reduced by targeting low HDL cholesterol. The 
ATP III guidelines state that LDL is the primary target and 
HDL should be addressed after non-HDL goals are met, the 
preferred drugs being nicotinic acid and fibrates. Nevertheless, 
there are a lot of emerging therapies such as CETP inhibitors, 
rHDL and Apo A-I Milano as well as HDL-mimetic peptides 
that exhibit promising results and certainly constitute a hope-
ful prospective in reducing CV events in our patients.
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